239
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Cystatin C as a Predictor of Major Adverse Cardiovascular Event in Patients with Acute Myocardial Infarction Without Cardiogenic Shock and Renal Impairment After Coronary Intervention

ORCID Icon, &
Pages 2219-2227 | Received 26 Apr 2023, Accepted 01 Jun 2023, Published online: 03 Jun 2023

References

  • Salgado JV, Neves FA, Bastos MG, et al. Monitoring renal function: measured and estimated glomerular filtration rates – a review. Braz J Med Biol Res. 2010;43(6):528–536. doi:10.1590/s0100-879x2010007500040
  • Xie L, Terrand J, Xu B, Tsaprailis G, Boyer J, Chen QM. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res. 2010;87(4):628–635. doi:10.1093/cvr/cvq138
  • Lassus J, Harjola VP, Cystatin C. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev. 2012;17(2):251–261. doi:10.1007/s10741-011-9242-6
  • Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med. 2017;376(21):2053–2064. doi:10.1056/NEJMra1606915
  • Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke Statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–e603. doi:10.1161/CIR.0000000000000485
  • Ibanez B, James S, Agewall S, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017;39(2):119–177.
  • Wasyanto T, Tridamayanti A. Blood urea nitrogen as a predictor of in-hospital mortality in acute coronary syndrome patients. Indonesian J Med. 2019;4(3):241–251. doi:10.26911/theijmed.2019.04.03.07
  • Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–2264. doi:10.1016/j.jacc.2018.08.1038
  • Přeček J, Hutyra M, Sněhota M, et al. Prognostic value of cystatin C in relation to other markers of renal function in early prediction of hospital mortality and major cardiac adverse events in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention. Cor Vasa. 2018;60(4):e352–e360. doi:10.1016/j.crvasa.2017.11.005
  • Abid L, Charfeddine S, Kammoun S, Turki M, Ayedi F. Cystatin C: a prognostic marker after myocardial infarction in patients without chronic kidney disease. J Saudi Heart Assoc. 2016;28(3):144–151. doi:10.1016/j.jsha.2015.10.001
  • Astor BC, Shafi T, Hoogeveen RC, et al. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012;59(5):653–662. doi:10.1053/j.ajkd.2011.11.042
  • Salgado JV, Souza FL, Salgado BJ. How to understand the association between cystatin C levels and cardiovascular disease: imbalance, counterbalance, or consequence? J Cardiol. 2013;62(6):331–335. doi:10.1016/j.jjcc.2013.05.015
  • Urbonaviciene G, Shi GP, Urbonavicius S, Henneberg EW, Lindholt JS. Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis. 2011;216(2):440–445. doi:10.1016/j.atherosclerosis.2011.02.016
  • Okura T, Jotoku M, Irita J, et al. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol. 2010;14(6):584–588. doi:10.1007/s10157-010-0334-8
  • Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009;55(11):19321943. doi:10.1373/clinchem.2009.128397